A new medical test developed by Renatek Co. Ltd. Is set to launch in Japan, offering a groundbreaking method to assess cancer and cognitive disorder risks through a simple blood sample. The test, known as the "Metalo-Balance Test," requires only 6 mL of blood, making it a non-invasive and efficient diagnostic tool. It is designed to detect early signs of cancer and mild cognitive impairment (MCI), a precursor to dementia. The test will be available at the Takeuchi Hospital in Nakagawa City, Gifu Prefecture, starting in December.
The Metalo-Balance Test analyzes the balance of metals in the blood, which are believed to be linked to the development of certain cancers and cognitive decline. Early detection of these conditions can significantly improve treatment outcomes and quality of life. The test is part of a growing trend in Japan toward more accessible and less invasive diagnostic methods.
Renatek Co. Ltd. Has been working on this technology for several years, focusing on the relationship between metal levels and health conditions. The company has partnered with medical professionals to ensure the accuracy and reliability of the test. This development comes as Japan faces an aging population and increasing concerns about neurodegenerative diseases. The launch of the test is expected to contribute to public health efforts by enabling earlier and more targeted interventions.
